Explore the words cloud of the HepatoPredict project. It provides you a very rough idea of what is the project "HepatoPredict" about.
The following table provides information about the project.
OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA LDA
|Coordinator Country||Portugal [PT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-08-01 to 2018-11-30|
Take a look of project's partnership.
|1||OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA LDA||PT (LISBOA)||coordinator||50˙000.00|
Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available organs, so stringent selection criteria are of paramount importance in order to ensure that the best candidates are selected for the procedure. So far, clinicians have to rely only on clinical variables to select transplant candidates for liver transplantation. The current criteria used (MILAN criteria) limits transplant to patients within specific parameters as tumour number and diameter, clearly related to disease and tumour biological behavior, but can only act as surrogate markers of tumour stage and biology. Hence, it is not possible to predict which patients outside the Milan criteria that would have a favourable prognosis. On this background, it is of outmost importance to gain access to better predictive tools that can provide decision support in selection for these patients. In response to this challenge, Ophiomics has developed a powerful predictive tool (HepatoPredict) based on molecular signature and clinical parameters, rather than only clinical variables. We can predict the good outcome of the intervention with a successful-curative rate of 82%, improving the Milan criteria one (67%). Unsuccessful liver transplantation will be avoided and, as a consequence, better survival rate and more saved lives will be achieved. Upon 5 years after the completion of the project, HepatoPredict will boost the growth of our company generating additional 15 FTEs and a ROI of 10.49. With the help of SME instrument, Ophiomics aims to complete the clinical validation and product optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the HCC patient´s quality of life.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPATOPREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEPATOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
Interactive Digital Signage with emotional intelligence for smart citiesRead More